+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018

  • ID: 4614603
  • Clinical Trials
  • June 2018
  • Region: Global
  • 474 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MORE
Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018

Summary

The author's clinical trial report, “Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018" provides an overview of Relapsed Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Relapsed Multiple Myeloma
Jun 17, 2018: Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
Jun 15, 2018: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma
Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label
Jun 01, 2018: Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Jun 01, 2018: Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
May 25, 2018: Glenmark Pharmaceuticals Announces Poster Presentation on GBR 1342 at 2018 ASCO Annual Meeting
May 17, 2018: PharmaMar Announces Data Presentations on its molecule Plitidepsin at ASCO 2018
May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
May 17, 2018: Genmab Announces Abstracts to be Presented on Daratumumab at 23rd EHA Annual Congress
May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018
May 16, 2018: bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
May 16, 2018: Janssen to Present Data on DARZALEX at ASCO 2018
May 16, 2018: Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions
Apr 30, 2018: Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS (carfilzomib) Label
Apr 28, 2018: BMS Phase 2 trial of the efficacy and safety of Elotuzumab
Apr 28, 2018: BMS Phase 2 single arm study of safety of Elotuzumab
Apr 25, 2018: Genmab to Present Data on Daratumumab at 2018 ASCO Annual Meeting
Apr 25, 2018: Incyte to Present Data from Phase 1 Study of Ruxolitinib at the 2018 ASCO Annual Meeting
Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin
Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
Apr 17, 2018: Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Disclaimer
Source

List of Tables
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*

List of Figures
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018*
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Celgene Corp
  • Johnson & Johnson
  • Amgen Inc
  • Takeda Pharmaceutical Co Ltd
  • Novartis AG
  • Bristol-Myers Squibb Co
  • AbbVie Inc
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd
  • Oncotherapeutics
Note: Product cover images may vary from those shown
Adroll
adroll